Video

Dr. Hainsworth on Selecting Therapy Based on Genetics

John D. Hainsworth, MD, co-founder; principal investigator, Sarah Cannon Research Institute, discusses the results of the MyPathway trial, which was an open-label, phase IIa umbrella basket study.

John D. Hainsworth, MD, co-founder; principal investigator, Sarah Cannon Research Institute, discusses the results of the MyPathway trial, which was an open-label, phase IIa basket study exploring treatments for patients with specific genetic alterations, regardless of histology.

The nationwide MyPathway study is an ongoing, non-randomized trial that is evaluating treatment options for patients with advanced cancer for whom no beneficial treatment is available. Patients, who must have tumors expressing abnormalities in the HER2, BRAF, hedgehog, or EGFR pathways, are matched with drugs targeting these abnormalities.

Patients with HER2-positive tumors received a combination of trastuzumab and pertuzumab, while those with BRAF alterations received vemurafenib. Hedgehog pathway-mutant tumors were treated with vismodegib, and erlotinib was given to patients with EGFR-mutant cancer.

In the trial, a total of 29 patients (23%) across 12 types of cancer responded to targeted treatment, and the most promising efficacy was seen in patients with HER2 abnormalities. Of those with HER2-abnormalities across 11 types of cancer, 28% (17/61) experienced a complete or partial response and 15% (9/61) had stable disease for more than 4 months.

<<<

View more from the 2016 ASCO Annual Meeting

Related Videos
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Kathleen N. Moore, MD, MS
Dana M. Chase, MD
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
R. Wendel Naumann, MD, professor and director of gynecologic oncology research, and associate medical director of clinical trials, Levine Cancer Institute, Atrium Health
Stéphanie Lheureux, MD, PhD, clinician investigator, Cancer Clinical Research Unit, Princess Margaret Cancer Centre